康泰生物(300601.SZ)：四价流感病毒裂解疫苗(6-35月龄人群)开启Ⅰ期临床试验

Core Viewpoint - Kangtai Biological (300601.SZ) has initiated Phase I clinical trials for its quadrivalent influenza virus split vaccine targeting the population aged 6 to 35 months, marking a significant step in its vaccine development efforts [1] Group 1: Clinical Development - The quadrivalent influenza virus split vaccine has completed preparations for Phase I clinical trials [1] - The first subject has been successfully enrolled in the Phase I clinical trial [1] Group 2: Vaccine Purpose and Importance - The vaccine is designed to stimulate the immune system to produce immunity against influenza viruses associated with the vaccine strains [1] - Influenza, caused by the influenza virus, is an acute respiratory infectious disease, and vaccination is the most effective and economical measure to prevent influenza and its outbreaks [1]